Inex/Hana licensing deal
Inex signed a Letter of Intent to license three chemotherapy pipeline products to Hana Biosciences, company announces. The oncologics include Marqibo (sphingosomal vincristine), INX-0125 (sphingosomal vinorelbine) and INX-0076 (sphingosomal topotecan). Inex/Enzon's Marqibo was deemed "not approvable" Jan. 14 following an Oncologic Drugs Advisory Committee recommendation against accelerated approval for third-line non-Hodgkin's lymphoma (1"The Pink Sheet" Dec. 6, 2004, p. 20). Under the deal, Hana will develop and commercialize the products and pay Inex $11.5 mil. in upfront payments. Inex also could receive $30.5 mil. in milestone payments...
You may also be interested in...
If President Trump appoints, and the Senate approves, a new conservative justice for the Supreme Court to replace Ruth Bader Ginsberg, Affordable Care Act coverage could disappear. See what Kyle Sampson, a partner with the Washington, DC law firm King & Spalding said about it here.
Join us for an audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
Keeping Track: New Nucala Indication; BMS’ Ide-Cel Clears Filing Hurdle; First Applications From Telix And ADC Therapeutics
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.